Exagen Inc. (NASDAQ:XGN) CEO Purchases $77,569.92 in Stock

Exagen Inc. (NASDAQ:XGNGet Free Report) CEO John Aballi purchased 40,401 shares of Exagen stock in a transaction that occurred on Thursday, May 16th. The shares were acquired at an average price of $1.92 per share, for a total transaction of $77,569.92. Following the acquisition, the chief executive officer now owns 40,401 shares in the company, valued at $77,569.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Exagen Price Performance

Shares of XGN opened at $1.88 on Friday. The company has a 50-day simple moving average of $1.54 and a two-hundred day simple moving average of $1.75. The company has a debt-to-equity ratio of 0.96, a quick ratio of 4.02 and a current ratio of 4.83. Exagen Inc. has a one year low of $1.30 and a one year high of $3.47.

Exagen (NASDAQ:XGNGet Free Report) last released its earnings results on Monday, March 18th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.02). The firm had revenue of $13.77 million during the quarter, compared to analysts’ expectations of $11.43 million. Exagen had a negative net margin of 34.74% and a negative return on equity of 75.86%. During the same quarter in the previous year, the business earned ($0.58) EPS. Research analysts anticipate that Exagen Inc. will post -1.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald boosted their target price on Exagen from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, May 14th.

Read Our Latest Report on Exagen

Institutional Trading of Exagen

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Perkins Capital Management Inc. increased its position in Exagen by 92.8% during the 4th quarter. Perkins Capital Management Inc. now owns 508,905 shares of the company’s stock valued at $1,013,000 after buying an additional 245,000 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of Exagen by 14.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,203,491 shares of the company’s stock worth $2,912,000 after purchasing an additional 154,139 shares during the last quarter. Finally, RTW Investments LP raised its position in shares of Exagen by 0.8% in the 4th quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock worth $2,994,000 after purchasing an additional 12,170 shares during the last quarter. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

(Get Free Report)

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Read More

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.